EUCTR2015-000399-81-DE进行中（未招募）1 期
AN INTERVENTIONAL, SINGLE ARM, PHASE I/IIA CLINICAL TRIAL TO INVESTIGATE THE EFFICACY AND SAFETY OF APZ2 ON WOUND HEALING OF CHRONIC VENOUS ULCER (CVU) - ABCB5+ cells for wound healing
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 37
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female patients aged 18 to 85 years;
- •2. Chronic venous leg ulcer (as defined by the current AWMF guidelines: therapy resistant ulcer that shows no improvement within 3 months despite of optimal phlebological therapies or is not healed within 12 months) for at least 6 weeks but shorter than 3 years diagnosed by doppler ultrasonography (DUS), ankle brachial index (ABI, 0.9–1.3), physical examination and dermatological review;
- •3. Wound size between 5 and 50 cm2 measured by a standardized photography at the screening visit;
- •4. Wound location between knee and ankle;
- •5. Patients suffering from 2 or more ulcers at the same extremity, as long as these ulcers are separated by a minimum bridge of 1 cm of epithelialized skin;
- •6. Patients must agree to have at least one biopsy performed before treatment. In case IMP production from the first biopsy is not successful, a second biopsy will be taken;
- •7. Body mass index (BMI) between 20 and 40 kg/m²;
- •8. Patients understand the nature of the procedure and are providing written informed consent prior to any clinical trial procedure;
- •9. Women of childbearing potential must have a negative blood pregnancy test at Screening and at Visit 5 before the IMP application;
- •10. Women of childbearing potential and their partner must be willing to use highly effective contraceptive methods during the course of the clinical trial.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 10
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 27
排除标准
- •General exclusion criteria
- •1. Evidence of the ulcer extending to the underlying muscle, tendon, or bone;
- •2. Current long-term use (more than 14 days) of steroid medication above Cushing-threshold dose (>7.5 mg/d prednisone or equivalent);
- •3. Diabetes mellitus that has to be evaluated by blood test (Hemoglobin A1c [HbA1c] > 7,5 %);
- •4. Peripheral Artery Disease (PAD) including claudication with need of treatment;
- •5. Acute deep vein thrombosis (maximum 30 days from diagnosis) or a still untreated deep vein thrombosis;
- •6. Unable to tolerate leg ulcer compression bandage;
- •7. Infection of the target ulcer requiring treatment as judged clinically;
- •8.Wound size <1.5 cm² measured by a standardized photography at Visit 5;
- •9. Any chronic dermatological disorders diagnosed at the investigator’s discretion;
- •10. Skin disorders, unrelated to the ulcer, that are present adjacent to the target wound;
- •11. Current use of medications that influence wound healing: systemic
- •immunosuppressives, cytotoxic medicinal products, and systemic steroids (above Cushing-threshold level);
- •12. Known abuse of alcohol, drugs, or medicinal products;
- •13. Cancerous or pre-cancerous lesions adjacent to the target wound;
- •14. Patients anticipated to be unwilling or unable to comply with the requirements of the protocol;
- •15. Pregnant or lactating women;
- •16. Systemic infectious disease diagnosed by serology testing for syphilis (acute), human immunodeficiency virus (HIV?1, HIV-2), hepatitis B (acute) or C infection at Screening or at Visit 2;
- •17. Any known allergies to components of the IMP;
- •18.Prior surgical procedures such as bypass or mesh-graft treatment within 2 months prior to IMP application;
- •19.Treatment of target ulcer with active wound care agents (e.g. Iruxol, local antibiotics or silver dressings), which have not been paused 14 days before IMP application;
- •20. Current or previous (within 30 days of enrollment) treatment with another IMP, or participation and/or under follow-up in another clinical trial;
- •21. Previous participation in this clinical trial;
- •22. Evidence of any other medical conditions (such as psychiatric illness, physical examination, or laboratory findings) that may interfere with the planned treatment, affect the patient’s compliance, or place the patient at high risk of complications related to the treatment;
- •23. Employees of the sponsor, or employees or relatives of the investigator.
- •Exclusion criteria for efficacy assessments
- •1. A wound size enlargement of more than 25% between the wound assessment at the screening visit and the wound assessment at Visit 5;
- •2. A wound size reduction of more than 50% between the wound assessment at the screening visit and wound assessment at Visit 5.
研究者
相似试验
尚未招募
2 期
Clinical Trial to evaluate the effectiveness of Thoothuvalai Nei in the treatment of Eraippu Noi (Childhood Bronchial Asthma) in ChildreCTRI/2023/06/054507Ayothidoss Pandithar Hospital, National Institute of Siddha
已完成
4 期
A clinical study to evaluate the efficacy and safety of NATBERB as a add on therapy for Type 2 diabetes MellitusCTRI/2023/04/051904Herbal Creations (A Unit of Kumaon Exports Pvt. Ltd.)46
进行中（未招募）
不适用
MESOT-TREM-2012EUCTR2012-002762-12-ITAZIENDA OSPEDALIERA SENESE
进行中（未招募）
不适用
A SECOND-LINE, SINGLE ARM, PHASE II CLINICAL STUDY WITH TREMELIMUMAB, A FULLY HUMANIZED ANTI-CTLA-4 MONOCLONAL ANTIBODY, AS MONOTHERAPY IN PATIENTS WITH UNRESECTABLE MALIGNANT MESOTHELIOMA - MESOT-TREM-2008PATIENTS WITH UNRESECTABLE MALIGNANT MESOTHELIOMAMedDRA version: 9.1Level: LLTClassification code 10059518Term: Pleural mesothelioma malignantEUCTR2008-005171-95-ITAZIENDA OSPEDALIERA SENESE
进行中（未招募）
1 期
Ex vivo drug sensitivity in metastatic colorectal cancerEUCTR2020-003395-41-NOOslo University Hospital45